By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Spark Therapeutics 

3737 Market Street
Suite 1300
Philadelphia  Pennsylvania  10104  U.S.A.
Phone: 888-772-7560 Fax: n/a


Spark Therapeutics is developing curative, one-time gene therapy products with the potential to transform the lives of patients and re-imagine the treatment of debilitating diseases. Spark's lead gene therapy candidate, for RPE65-related blindness, is currently in Phase 3 clinical trials with the potential to be the first approved gene therapy in the United States, and the first approved treatment to address the significant unmet needs of patients living with blindness due to inherited retinal dystrophies.

Additionally, the company has clinical and preclinical programs in other inherited retinal dystrophies and hematological disorders, and a proprietary manufacturing platform that has successfully supported human gene therapy trials across diverse therapeutic areas and routes of administration. Spark’s founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines.

Spark is based in Philadelphia, PA and was spun out of The Children's Hospital of Philadelphia in October 2013. In May 2014, Spark announced the completion of a $72.8 million Series B financing led by Sofinnova Ventures, bringing the company's total funding raised to $82.8 million to-date. To learn more about Spark visit




Founders: Jeffrey Marrazzo, J. Fraser Wright and Katherine High

CEO: Jeffrey Marrazzo

CTO: J. Fraser Wright

CSO (Scientific): Katherine High


Please click here for Spark Therapeutics job opportunities.


Please click here for clinical trial information.


Key Statistics

Ownership: Public

Web Site: Spark Therapeutics
Employees: n/a
Symbol: ONCE


Company News
Spark Therapeutics (ONCE) Announces Publication Of Study Confirming Novel Test’s Validity, Reliability And Ability To Detect Change In Functional Vision 9/6/2017 10:13:52 AM
Why You Shouldn't Fear Spark Therapeutics (ONCE)' Upcoming Share Issue 8/7/2017 6:19:39 AM
Spark Therapeutics (ONCE) Announces Pricing Of $350.0 Million Public Offering 8/4/2017 8:03:14 AM
Spark Therapeutics (ONCE) Announces Proposed Public Offering Of Common Stock 8/3/2017 11:54:55 AM
Spark Therapeutics (ONCE) Unveils Encouraging Hemophilia A Data 8/2/2017 1:22:03 PM
Spark Therapeutics (ONCE) Receives Rare Pediatric Disease Designation For Investigational LUXTURNA (Voretigene Neparvovec) From FDA 7/20/2017 11:51:44 AM
Spark Therapeutics (ONCE)’ Biologics License Application For Investigational Voretigene Neparvovec Accepted For Filing By FDA 7/17/2017 10:25:28 AM
Spark Therapeutics (ONCE) Announces Publication In The Lancet Of Pivotal Phase III Clinical Trial Data For Investigational Voretigene Neparvovec 7/14/2017 10:41:07 AM
Spark Therapeutics (ONCE): The Next Big Thing In Gene Therapy? 5/26/2017 5:49:40 AM
Massachusetts' Selecta (SELB) Wrangles $890 Million+ R&D Deal Out of Spark Therapeutics (ONCE) 12/5/2016 5:44:25 AM